BioNTech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

BioNTech şirketinin toplam hissedar öz sermayesi €19.1B ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €22.4B ve €3.3B dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€16.71b
Eşitlik	€19.11b
Toplam yükümlülükler	€3.29b
Toplam varlıklar	€22.40b

Son finansal sağlık güncellemeleri

Recent updates

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

Nov 06

BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates

Nov 06

BioNTech's Oncology Gamble: High Stakes, Big Potential

Oct 21

BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth

Sep 13

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Aug 20

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

Aug 06

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

Jun 16

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

May 08

BioNTech Earnings Preview: I Will Stay On The Sidelines

May 03

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Apr 22

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BNTX 'nin kısa vadeli varlıkları ( €18.5B ) kısa vadeli yükümlülüklerini ( €2.5B ) aşıyor.

Uzun Vadeli Yükümlülükler: BNTX şirketinin kısa vadeli varlıkları ( €18.5B ) uzun vadeli yükümlülüklerini ( €764.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BNTX borçsuzdur.

Borcun Azaltılması: BNTX şirketinin 5 yıl önce borç/öz sermaye oranı 3.3% iken borcu yok.

Borç Kapsamı: BNTX un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: BNTX şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

BioNTech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

Consensus EPS estimates fall by 15%

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

New major risk - Revenue and earnings growth

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech's Oncology Gamble: High Stakes, Big Potential

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Consensus EPS estimates fall by 10%

New major risk - Revenue and earnings growth

BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Consensus EPS estimates fall by 24%

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to €1.74 loss

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BioNTech Earnings Preview: I Will Stay On The Sidelines

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Consensus EPS estimates fall by 11%

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Consensus EPS estimates have been downgraded.

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Now 21% undervalued after recent price drop

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 13%

Independent Supervisory Board Chairman notifies of intention to sell stock

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023